Scientific publications

Modulating T Cell Responses by Targeting CD3. Scientific Publication

Feb 13, 2024 | Magazine: Cancers

Ashwathi Puravankara Menon 1 2, Beatriz Moreno 1, Daniel Meraviglia-Crivelli 1 2, Francesca Nonatelli 1, Helena Villanueva 1 2, Martin Barainka 1 2, Angelina Zheleva 1 2, Hisse M van Santen 3, Fernando Pastor 1 2


Abstract

Harnessing the immune system to fight cancer has become a reality with the clinical success of immune-checkpoint blockade (ICB) antibodies against PD(L)-1 and CTLA-4. However, not all cancer patients respond to ICB.

Thus, there is a need to modulate the immune system through alternative strategies for improving clinical responses to ICB. The CD3-T cell receptor (TCR) is the canonical receptor complex on T cells. It provides the "first signal" that initiates T cell activation and determines the specificity of the immune response. The TCR confers the binding specificity whilst the CD3 subunits facilitate signal transduction necessary for T cell activation.

While the mechanisms through which antigen sensing and signal transduction occur in the CD3-TCR complex are still under debate, recent revelations regarding the intricate 3D structure of the CD3-TCR complex might open the possibility of modulating its activity by designing targeted drugs and tools, including aptamers. In this review, we summarize the basis of CD3-TCR complex assembly and survey the clinical and preclinical therapeutic tools available to modulate CD3-TCR function for potentiating cancer immunotherapy.

CITATION Cancers (Basel). 2023 Feb 13;15(4):1189. doi: 10.3390/cancers15041189.

Our authors

Investigadora del Programa de Terapias Moleculares del Cima Universidad de Navarra
Dr. Beatriz Moreno Bruna
Research Collaborator Aptamers Research Group
Helena Villanueva Ruiz
Research Technician Aptamers Research Group
Dr. Angelina Zheleva